18.7.4: Results Antibiotic Susceptibility Testing
- Page ID
- 122909
\( \newcommand{\vecs}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \) \( \newcommand{\vecd}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash {#1}}} \)\(\newcommand{\id}{\mathrm{id}}\) \( \newcommand{\Span}{\mathrm{span}}\) \( \newcommand{\kernel}{\mathrm{null}\,}\) \( \newcommand{\range}{\mathrm{range}\,}\) \( \newcommand{\RealPart}{\mathrm{Re}}\) \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\) \( \newcommand{\Argument}{\mathrm{Arg}}\) \( \newcommand{\norm}[1]{\| #1 \|}\) \( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\) \( \newcommand{\Span}{\mathrm{span}}\) \(\newcommand{\id}{\mathrm{id}}\) \( \newcommand{\Span}{\mathrm{span}}\) \( \newcommand{\kernel}{\mathrm{null}\,}\) \( \newcommand{\range}{\mathrm{range}\,}\) \( \newcommand{\RealPart}{\mathrm{Re}}\) \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\) \( \newcommand{\Argument}{\mathrm{Arg}}\) \( \newcommand{\norm}[1]{\| #1 \|}\) \( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\) \( \newcommand{\Span}{\mathrm{span}}\)\(\newcommand{\AA}{\unicode[.8,0]{x212B}}\)
Interpret the results following steps 9 and 10 of the procedure and record your results in the tables below.
Staphylococcus aureus
| Disc code | Antimicrobial agent | Zone in mm | R | I | MS | S |
|---|---|---|---|---|---|---|
| AMC-30 | amoxicillin/ clavulanic acid |
|||||
| CTX-30 | cefotaxime | |||||
| FOX-30 | cefoxitin | |||||
| CIP-5 | ciprofloxacin | |||||
| DA-2 | clindamycin | |||||
| E-15 | erythromycin | |||||
| K-30 | kanamycin | |||||
| OX-1 | oxacillin | |||||
| SXT-25 | sulfamethoxazole + trimethoprim |
|||||
| TE-30 | tetracycline | |||||
| TZP110 | piperacillin/tazobactum | |||||
| VA-30 | vancomycin |
R = Resistant
I = Intermediate
MS = Moderately Susceptible
S = Susceptible
| Disc code | Antimicrobial agent | Zone in mm | R | I | MS | S |
|---|---|---|---|---|---|---|
| AMC-30 | amoxicillin/ clavulanic acid |
|||||
| CTX-30 | cefotaxime | |||||
| FOX-30 | cefoxitin | |||||
| CIP-5 | ciprofloxacin | |||||
| DA-2 | clindamycin | |||||
| E-15 | erythromycin | |||||
| K-30 | kanamycin | |||||
| OX-1 | oxacillin | |||||
| SXT-25 | sulfamethoxazole + trimethoprim |
|||||
| TE-30 | tetracycline | |||||
| TZP-110 | piperacillin/tazobactum | |||||
| VA-30 | vancomycin |
R = Resistant
I = Intermediate
MS = Moderately Susceptible
S = Susceptible
| disc code | antimicrobial agent | zone in mm | R | I | MS | S |
|---|---|---|---|---|---|---|
| AK-30 | amikacin | |||||
| AMC-30 | amoxicillin/ clavulanic acid |
|||||
| AMP-10 | ampicillin | |||||
| MEZ-75 | mezlocillin | |||||
| CTX-30 | cefotaxime | |||||
| FOX-30 | cefoxitin | |||||
| CIP-5 | ciprofloxacin | |||||
| CN-10 | gentamicin | |||||
| K-30 | kanamycin | |||||
| SXT-25 | sulfamethoxazole + trimethoprim |
|||||
| TE-30 | tetracycline | |||||
| TZP-110 | piperacillin/tazobactum |
R = Resistant
I = Intermediate
MS = Moderately Susceptible
S = Susceptible
Contributors and Attributions
Dr. Gary Kaiser (COMMUNITY COLLEGE OF BALTIMORE COUNTY, CATONSVILLE CAMPUS)